ADIM
MCRB icon

Alpha DNA Investment Management’s Seres Therapeutics MCRB Stock Holding History

Alpha DNA Investment Management’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-6,927
Closed -$664K – 204
2023
Q2 		$664K Buy
+6,927
New +$754K 0.22% 137

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Alpha DNA Investment Management's MCRB Position: Q3 2023 in Review

Alpha DNA Investment Management sold out of Seres Therapeutics (MCRB) in Q3 2023, closing a stake of 6,927 shares — an estimated $664K sold.

Alpha DNA Investment Management first reported a position in MCRB in Q2 2023 and held it in 1 quarter. The position peaked at $664K in Q2 2023. 134 funds tracked by Wall St. Rank hold MCRB as of Q3 2023.

  • Alpha DNA Investment Management reported no remaining Seres Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Alpha DNA Investment Management sold 6,927 Seres Therapeutics shares in Q3 2023, an estimated $664K.
  • Alpha DNA Investment Management first reported a position in Seres Therapeutics in Q2 2023 and held it in 1 quarter.
  • Alpha DNA Investment Management's Seres Therapeutics position peaked at $664K in Q2 2023.
  • 134 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2023.

Based on Alpha DNA Investment Management's 13F filing for Q3 2023, filed 7 Nov 2023.